Nuvation Bio Inc (NUVB)

$5.09 +0.24 (4.95%)
Market Cap 1.66B
Revenue (ttm) 7.87M
Net Income (ttm) -567.94M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -7,216.52%
Debt to Equity Ratio 0.14
Volume 5,649,186
Avg Vol 6,983,724
Day's Range N/A - N/A
Shares Out 342.27M
Stochastic %K 99%
Beta 1.48
Analysts Strong Sell
Price Target $8.17

Company Profile

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutic candidates for oncology. Its lead product candidate is taletrectinib, an ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. The company is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 2 clinical trials; NUV-1511, a drug-drug conjugate for use in chemotherapy agent that suppresses the growth of various advanced solid tumors; a...

Industry: Biotechnology
Sector: Healthcare
Phone: 332 208 6102
Address:
1500 Broadway, Suite 1401, New York, United States
topstockalerts
topstockalerts Oct. 27 at 6:11 PM
$NUVB heating up….
0 · Reply
sv__
sv__ Oct. 27 at 6:08 PM
$NUVB Chill like my beardie.😂
0 · Reply
GMEryder
GMEryder Oct. 27 at 6:07 PM
$NUVB im looking for a good entry back here as the ER is next week I think this could easily double after they reveal financials and how much customers are enrolled so far This could move very fast ✌🏻
0 · Reply
searchthealley
searchthealley Oct. 27 at 5:55 PM
$NUVB o yahhh lovely
0 · Reply
ISEEITALLTHETIME
ISEEITALLTHETIME Oct. 27 at 5:53 PM
$NUVB Absolutely not!
0 · Reply
Willreid795
Willreid795 Oct. 27 at 5:44 PM
$NUVB I think this reaches $6 by Monday afternoon before earnings. Clear skies on the forecast
0 · Reply
2Pennies4Tendies
2Pennies4Tendies Oct. 27 at 5:43 PM
$NUVB Can't wait for earnings 🔥🔥
0 · Reply
marti837
marti837 Oct. 27 at 5:28 PM
$NUVB take profit
0 · Reply
VishalMathew
VishalMathew Oct. 27 at 5:26 PM
$NUVB I think this will continue till ER
0 · Reply
Social_Idiot
Social_Idiot Oct. 27 at 5:13 PM
$NUVB Like 5$ has Cooties.
0 · Reply
Latest News on NUVB
Nuvation Bio Enrolls First Patient in Global, Randomized Study of Safusidenib for Maintenance Treatment of High-Grade IDH1-Mutant Glioma

Oct 23, 2025, 7:30 AM EDT - 4 days ago

Nuvation Bio Enrolls First Patient in Global, Randomized Study of Safusidenib for Maintenance Treatment of High-Grade IDH1-Mutant Glioma

Nuvation Bio to Report Third Quarter 2025 Financial Results and Provide Business Update on November 3, 2025

Oct 20, 2025, 4:05 PM EDT - 6 days ago

Nuvation Bio to Report Third Quarter 2025 Financial Results and Provide Business Update on November 3, 2025

Nuvation Bio Enrolls First Patient in TRUST-IV Phase 3 Study of IBTROZI™ (taletrectinib) for the Adjuvant Treatment of ROS1-Positive Early-Stage Non-Small Cell Lung Cancer

Sep 30, 2025, 7:30 AM EDT - 27 days ago

Nuvation Bio Enrolls First Patient in TRUST-IV Phase 3 Study of IBTROZI™ (taletrectinib) for the Adjuvant Treatment of ROS1-Positive Early-Stage Non-Small Cell Lung Cancer

3 Of My Favorite Biotech Stocks Under $10

Sep 29, 2025, 1:15 PM EDT - 4 weeks ago

3 Of My Favorite Biotech Stocks Under $10

DVAX FOLD MRNA PFE

Nuvation Bio Receives Approval from Japan's Ministry of Health, Labour and Welfare for IBTROZITM for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer

Sep 19, 2025, 7:30 AM EDT - 5 weeks ago

Nuvation Bio Receives Approval from Japan's Ministry of Health, Labour and Welfare for IBTROZITM for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer

Nuvation Bio: A Rare Gem In The Risky Biotech Space

Sep 15, 2025, 12:27 PM EDT - 6 weeks ago

Nuvation Bio: A Rare Gem In The Risky Biotech Space

Nuvation Bio Announces New Data from Pivotal Clinical Studies of IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at 2025 World Conference on Lung Cancer

Sep 7, 2025, 6:00 AM EDT - 7 weeks ago

Nuvation Bio Announces New Data from Pivotal Clinical Studies of IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at 2025 World Conference on Lung Cancer

Top 2 Health Care Stocks That May Plunge This Month

Sep 5, 2025, 10:39 AM EDT - 7 weeks ago

Top 2 Health Care Stocks That May Plunge This Month

ESPR

Nuvation Bio: What To Expect From IBTROZI Launch?

Aug 28, 2025, 12:16 PM EDT - 2 months ago

Nuvation Bio: What To Expect From IBTROZI Launch?

Nuvation Bio to Participate in Upcoming Investor Conferences

Aug 27, 2025, 4:05 PM EDT - 2 months ago

Nuvation Bio to Participate in Upcoming Investor Conferences

Nuvation Bio Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 7, 2025, 7:30 AM EDT - 2 months ago

Nuvation Bio Reports Second Quarter 2025 Financial Results and Provides Business Update

Nuvation Bio To Present New Data on IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses

Aug 5, 2025, 8:00 AM EDT - 2 months ago

Nuvation Bio To Present New Data on IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses

Nuvation Bio to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025

Jul 24, 2025, 4:05 PM EDT - 3 months ago

Nuvation Bio to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025

Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI™) as Preferred Option to Clinical Practice Guidelines in Oncology for Advanced ROS1+ Non-Small Cell Lung Cancers

Jun 24, 2025, 7:00 AM EDT - 4 months ago

Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI™) as Preferred Option to Clinical Practice Guidelines in Oncology for Advanced ROS1+ Non-Small Cell Lung Cancers

Onco360 Has Been Selected as a National Specialty Pharmacy Partner for IBTROZI™ (taletrectinib), Manufactured by Nuvation Bio Inc.

Jun 16, 2025, 7:30 AM EDT - 4 months ago

Onco360 Has Been Selected as a National Specialty Pharmacy Partner for IBTROZI™ (taletrectinib), Manufactured by Nuvation Bio Inc.

US FDA approves Nuvation Bio's lung cancer therapy

Jun 11, 2025, 1:45 PM EDT - 4 months ago

US FDA approves Nuvation Bio's lung cancer therapy

U.S. Food and Drug Administration Approves Nuvation Bio's IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer

Jun 11, 2025, 1:20 PM EDT - 4 months ago

U.S. Food and Drug Administration Approves Nuvation Bio's IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer

Nuvation Bio To Present New Data from Pivotal Clinical Studies of Taletrectinib in Advanced ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2025 Annual Meeting

May 21, 2025, 4:05 PM EDT - 5 months ago

Nuvation Bio To Present New Data from Pivotal Clinical Studies of Taletrectinib in Advanced ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2025 Annual Meeting

Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Entrectinib at ISPOR 2025

May 13, 2025, 4:05 PM EDT - 5 months ago

Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Entrectinib at ISPOR 2025

Nuvation Bio Inc. (NUVB) Q1 2025 Earnings Call Transcript

May 11, 2025, 10:05 PM EDT - 6 months ago

Nuvation Bio Inc. (NUVB) Q1 2025 Earnings Call Transcript

Nuvation Bio Reports First Quarter 2025 Financial Results and Provides Business Update

May 7, 2025, 4:05 PM EDT - 6 months ago

Nuvation Bio Reports First Quarter 2025 Financial Results and Provides Business Update

Nuvation Bio: A Real Shot To Move The Needle In Lung Cancer Subtypes

May 7, 2025, 9:07 AM EDT - 6 months ago

Nuvation Bio: A Real Shot To Move The Needle In Lung Cancer Subtypes

Nuvation Bio to Present at The Citizens Life Sciences Conference

May 1, 2025, 4:05 PM EDT - 6 months ago

Nuvation Bio to Present at The Citizens Life Sciences Conference

Nuvation Bio to Report Results for First Quarter 2025 and Provide Business Update on May 7, 2025

Apr 22, 2025, 4:05 PM EDT - 6 months ago

Nuvation Bio to Report Results for First Quarter 2025 and Provide Business Update on May 7, 2025

Nuvation Bio to Present at the Jones Healthcare and Technology Innovation Conference

Apr 2, 2025, 8:00 AM EDT - 7 months ago

Nuvation Bio to Present at the Jones Healthcare and Technology Innovation Conference

Nuvation Bio to Present New Nonclinical Data for Taletrectinib at the American Association for Cancer Research Annual Meeting 2025

Mar 25, 2025, 4:45 PM EDT - 7 months ago

Nuvation Bio to Present New Nonclinical Data for Taletrectinib at the American Association for Cancer Research Annual Meeting 2025

Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Crizotinib During Mini Oral Presentation at the European Lung Cancer Congress 2025

Mar 25, 2025, 8:00 AM EDT - 7 months ago

Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Crizotinib During Mini Oral Presentation at the European Lung Cancer Congress 2025

Nuvation Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 6, 2025, 4:30 PM EST - 8 months ago

Nuvation Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Nuvation Bio Secures Up to $250 Million in Non-Dilutive Financings from Sagard Healthcare Partners

Mar 3, 2025, 8:35 AM EST - 8 months ago

Nuvation Bio Secures Up to $250 Million in Non-Dilutive Financings from Sagard Healthcare Partners

Nuvation Bio to Present at the TD Cowen 45th Annual Health Care Conference

Feb 24, 2025, 8:00 AM EST - 8 months ago

Nuvation Bio to Present at the TD Cowen 45th Annual Health Care Conference

Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm

Feb 18, 2025, 1:49 PM EST - 8 months ago

Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm

Nuvation Bio: Pending Approval Shot In ROSL+ NSCLS Looks A Major Upside Catalyst

Feb 13, 2025, 5:09 PM EST - 9 months ago

Nuvation Bio: Pending Approval Shot In ROSL+ NSCLS Looks A Major Upside Catalyst

Nuvation Bio Announces Expanded Access Program in the U.S. for Taletrectinib in Advanced ROS1-positive Non-Small Cell Lung Cancer

Feb 3, 2025, 8:00 AM EST - 9 months ago

Nuvation Bio Announces Expanded Access Program in the U.S. for Taletrectinib in Advanced ROS1-positive Non-Small Cell Lung Cancer

Nuvation Bio to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 6, 2025, 4:05 PM EST - 10 months ago

Nuvation Bio to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Nuvation Bio Receives Approval from China's National Medical Products Administration for Taletrectinib for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer

Jan 6, 2025, 8:00 AM EST - 10 months ago

Nuvation Bio Receives Approval from China's National Medical Products Administration for Taletrectinib for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer

Innovent Announces Second New Drug Application of DOVBLERON ® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) was Approved by China's National Medical Products Administration

Jan 2, 2025, 7:00 PM EST - 10 months ago

Innovent Announces Second New Drug Application of DOVBLERON ® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) was Approved by China's National Medical Products Administration

U.S. Food and Drug Administration Accepts for Priority Review Nuvation Bio's New Drug Application for Taletrectinib for the Treatment of Advanced ROS1-positive Non-Small Cell Lung Cancer

Dec 23, 2024, 8:00 AM EST - 11 months ago

U.S. Food and Drug Administration Accepts for Priority Review Nuvation Bio's New Drug Application for Taletrectinib for the Treatment of Advanced ROS1-positive Non-Small Cell Lung Cancer

Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration

Dec 20, 2024, 7:10 AM EST - 11 months ago

Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration

Nuvation Bio to Present at the 7th Annual Evercore ISI HealthCONx Conference

Nov 26, 2024, 8:00 AM EST - 11 months ago

Nuvation Bio to Present at the 7th Annual Evercore ISI HealthCONx Conference

Nuvation Bio to Present at the Jefferies London Healthcare Conference

Nov 12, 2024, 4:05 PM EST - 1 year ago

Nuvation Bio to Present at the Jefferies London Healthcare Conference

Top 4 Health Care Stocks That May Plunge This Quarter

Nov 11, 2024, 6:18 AM EST - 1 year ago

Top 4 Health Care Stocks That May Plunge This Quarter

AIRS PODD QDEL

Nuvation Bio Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 6, 2024, 4:05 PM EST - 1 year ago

Nuvation Bio Reports Third Quarter 2024 Financial Results and Provides Business Update

Nuvation Bio Appoints Industry Veteran Philippe Sauvage as Chief Financial Officer

Oct 7, 2024, 4:05 PM EDT - 1 year ago

Nuvation Bio Appoints Industry Veteran Philippe Sauvage as Chief Financial Officer

Positive Pooled Data from Nuvation Bio's TRUST-I and TRUST-II Studies Highlight Taletrectinib's Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024

Sep 14, 2024, 3:05 AM EDT - 1 year ago

Positive Pooled Data from Nuvation Bio's TRUST-I and TRUST-II Studies Highlight Taletrectinib's Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024

Nuvation Bio to Present at the Cantor Global Healthcare Conference

Sep 9, 2024, 8:00 AM EDT - 1 year ago

Nuvation Bio to Present at the Cantor Global Healthcare Conference

Nuvation Bio: Continuing To Justify A Buy Thesis With Catalysts In 2024

Aug 8, 2024, 3:51 PM EDT - 1 year ago

Nuvation Bio: Continuing To Justify A Buy Thesis With Catalysts In 2024

Nuvation Bio Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 5, 2024, 8:00 AM EDT - 1 year ago

Nuvation Bio Reports Second Quarter 2024 Financial Results and Provides Business Update

Nuvation Bio Announces Updates and Upcoming Presentations for its ROS1 Inhibitor, Taletrectinib

Jul 23, 2024, 4:05 PM EDT - 1 year ago

Nuvation Bio Announces Updates and Upcoming Presentations for its ROS1 Inhibitor, Taletrectinib

Innovent Announces Taletrectinib（ROS1 Inhibitor）Updated Data from Pivotal Phase 2 TRUST-I Study of are Published in the JCO and Orally Presentedat 2024 ASCO Annual Meeting

Jun 2, 2024, 1:13 AM EDT - 1 year ago

Innovent Announces Taletrectinib（ROS1 Inhibitor）Updated Data from Pivotal Phase 2 TRUST-I Study of are Published in the JCO and Orally Presentedat 2024 ASCO Annual Meeting

Innovent Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib（ROS1 Inhibitor) are Published in the JCO and Reported at 2024 ASCO Annual Meeting

Jun 1, 2024, 8:00 PM EDT - 1 year ago

Innovent Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib（ROS1 Inhibitor) are Published in the JCO and Reported at 2024 ASCO Annual Meeting

topstockalerts
topstockalerts Oct. 27 at 6:11 PM
$NUVB heating up….
0 · Reply
sv__
sv__ Oct. 27 at 6:08 PM
$NUVB Chill like my beardie.😂
0 · Reply
GMEryder
GMEryder Oct. 27 at 6:07 PM
$NUVB im looking for a good entry back here as the ER is next week I think this could easily double after they reveal financials and how much customers are enrolled so far This could move very fast ✌🏻
0 · Reply
searchthealley
searchthealley Oct. 27 at 5:55 PM
$NUVB o yahhh lovely
0 · Reply
ISEEITALLTHETIME
ISEEITALLTHETIME Oct. 27 at 5:53 PM
$NUVB Absolutely not!
0 · Reply
Willreid795
Willreid795 Oct. 27 at 5:44 PM
$NUVB I think this reaches $6 by Monday afternoon before earnings. Clear skies on the forecast
0 · Reply
2Pennies4Tendies
2Pennies4Tendies Oct. 27 at 5:43 PM
$NUVB Can't wait for earnings 🔥🔥
0 · Reply
marti837
marti837 Oct. 27 at 5:28 PM
$NUVB take profit
0 · Reply
VishalMathew
VishalMathew Oct. 27 at 5:26 PM
$NUVB I think this will continue till ER
0 · Reply
Social_Idiot
Social_Idiot Oct. 27 at 5:13 PM
$NUVB Like 5$ has Cooties.
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Oct. 27 at 4:51 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $NUVB Current Share Price: $5.00 Contracts: $NUVB January 15, 2027 $5 Calls Scale in: $2.24- $2.74 Scale out: $3.49-$4.48 Can Easily Capture: 60% ROI Blended DTE: 445 Days | Join Elites here: https://liquidtheta.com
0 · Reply
Doc_G
Doc_G Oct. 27 at 4:48 PM
$NUVB gimmie 5
0 · Reply
BioCapitalist99
BioCapitalist99 Oct. 27 at 4:37 PM
$CCCC $IMRX $NUVB $SLS $TNXP
0 · Reply
BioCapitalist99
BioCapitalist99 Oct. 27 at 4:37 PM
$NUVB
0 · Reply
cled
cled Oct. 27 at 4:30 PM
$NUVB
0 · Reply
AdiDasRom
AdiDasRom Oct. 27 at 3:52 PM
$NUVB
0 · Reply
ISEEITALLTHETIME
ISEEITALLTHETIME Oct. 27 at 3:26 PM
$NUVB This will close above $5 today.
1 · Reply
Bio_Invest101
Bio_Invest101 Oct. 27 at 2:39 PM
$NUVB over 2 million shares traded in 1st hour and the major indexes are all recorded historical highs with IWM at all time highs too Retails sell and funds buy plus Shorts keep digging deeper and wider until the sky falling down to cover for them. Great movie to watch in real time. Strong hold for 3rd Q ER
0 · Reply
AdiDasRom
AdiDasRom Oct. 27 at 2:38 PM
$NUVB I think it will decrease for a while and then resume growth.
0 · Reply
BiotechBonesaw
BiotechBonesaw Oct. 27 at 2:35 PM
$SLS $TNXP i own boyh plus lots of $NUVB $IMRX and $CCCC holding long 🚀
0 · Reply
Frida_m
Frida_m Oct. 27 at 2:28 PM
$NUVB RNA bought out by Novartis today for $72 cash per share. No approved products. Anything can happen here.
1 · Reply
Freiburg101
Freiburg101 Oct. 27 at 1:49 PM
$NUVB Something is cooking here, unusually high PM volume today, almost 850k shares already traded…Normally NUVB doesn‘t have a real PM action at all, will be interesting to see how today goes, shorts should be worried imo🤷
1 · Reply